Mesoblast Ltd. (MESO)
18.18
+1.34
(+7.96%)
USD |
NASDAQ |
Aug 27, 16:00
17.85
-0.33
(-1.82%)
Pre-Market: 08:04
Mesoblast Price to Book Value : 3.109 for Aug. 27, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 3.109 |
| August 26, 2026 | 2.880 |
| August 25, 2026 | 2.940 |
| August 24, 2026 | 2.846 |
| August 21, 2026 | 2.907 |
| August 20, 2026 | 2.981 |
| August 19, 2026 | 2.929 |
| August 18, 2026 | 2.851 |
| August 17, 2026 | 2.910 |
| August 14, 2026 | 2.667 |
| August 13, 2026 | 2.820 |
| August 12, 2026 | 2.869 |
| August 11, 2026 | 2.893 |
| August 10, 2026 | 2.852 |
| August 07, 2026 | 2.726 |
| August 06, 2026 | 2.671 |
| August 05, 2026 | 2.558 |
| August 04, 2026 | 2.531 |
| August 03, 2026 | 2.474 |
| July 31, 2026 | 2.423 |
| July 30, 2026 | 2.488 |
| July 29, 2026 | 2.416 |
| July 28, 2026 | 2.471 |
| July 27, 2026 | 2.490 |
| July 24, 2026 | 2.618 |
| Date | Value |
|---|---|
| July 23, 2026 | 2.750 |
| July 22, 2026 | 2.787 |
| July 21, 2026 | 2.808 |
| July 20, 2026 | 2.844 |
| July 17, 2026 | 2.962 |
| July 16, 2026 | 3.054 |
| July 15, 2026 | 3.119 |
| July 14, 2026 | 2.863 |
| July 13, 2026 | 2.774 |
| July 10, 2026 | 2.640 |
| July 09, 2026 | 2.536 |
| July 08, 2026 | 2.531 |
| July 07, 2026 | 2.444 |
| July 06, 2026 | 2.450 |
| July 02, 2026 | 2.459 |
| July 01, 2026 | 2.409 |
| June 30, 2026 | 2.314 |
| June 29, 2026 | 2.327 |
| June 26, 2026 | 2.256 |
| June 25, 2026 | 2.480 |
| June 24, 2026 | 2.659 |
| June 23, 2026 | 2.63 |
| June 22, 2026 | 2.651 |
| June 18, 2026 | 2.457 |
| June 17, 2026 | 2.389 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Immutep Ltd. | -- |
| CSL Ltd. | -- |
| Ceryvyn Therapeutics Ltd. | -- |
| Propanc Biopharma, Inc. | 0.1984 |
| Actinogen Medical Ltd. | -- |
Price to Book Value Related Metrics
| PS Ratio | 19.52 |
| Price | 18.18 |
| Earnings Yield | -2.45% |
| Market Cap | 2.343B |